A Phase 1/2, Open-Label, Randomized Parallel Arm, Intra-patient Dose Titration Study to Evaluate Safety, PK and Preliminary Efficacy of CNSA-001 in Adult/Adolescent Primary Tetrahydrobiopterin Deficient Patients With Hyperphenylalaninemia
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2018
At a glance
- Drugs CNSA-001 (Primary)
- Indications Hyperphenylalaninaemia
- Focus Adverse reactions; Proof of concept
- Sponsors Censa Pharmaceuticals
- 15 Oct 2018 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.
- 15 Oct 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Mar 2019.
- 19 Jul 2018 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.